Your Molecule
Your Molecule
Virus and Viral Vector Formulation
Virus and Viral Vector Formulation
Stabilization strategies tailored to virus structure, vector type and delivery needs.
Early risk identification to design stable, patient-ready drug products
Why viral vector formulation matters
Why viral vector formulation matters
Biologic products based on viruses are among the most structurally fragile molecules in drug development. They are prone to aggregation, shear sensitivity, envelope disruption, and chemical degradation. Whether used as gene therapy vectors, oncolytic viruses, or vaccine platforms, viral therapeutics require intelligent, fine-tuned formulation to maintain potency, safety, and manufacturability.
With experience in more than 100 virus-based projects, Leukocare has built a unique formulation knowledge base spanning enveloped and non-enveloped viruses, DNA and RNA virus types, virus-like particles (VLPs), viral vector-based gene therapies, and both live-attenuated and inactivated vaccines.
Explore our full modalities hub
Biologic products based on viruses are among the most structurally fragile molecules in drug development. They are prone to aggregation, shear sensitivity, envelope disruption, and chemical degradation. Whether used as gene therapy vectors, oncolytic viruses, or vaccine platforms, viral therapeutics require intelligent, fine-tuned formulation to maintain potency, safety, and manufacturability.
With experience in more than 100 virus-based projects, Leukocare has built a unique formulation knowledge base spanning enveloped and non-enveloped viruses, DNA and RNA virus types, virus-like particles (VLPs), viral vector-based gene therapies, and both live-attenuated and inactivated vaccines.
Explore our full modalities hub
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
What we work with
a
Can we add some text here?
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
text for spacing
Improved stability at almost 2x the antibody concentration
Case Study
We have optimized antibody formulations above 200 mg/mL for pre-filled syringe use, meeting stability, viscosity and usability criteria through advanced excipient systems and process .
Up-concentrating and antibody using a standard formulation does not always result in a stable drug product. The up-concentrated commercially available formulation (red) is significantly less stable as it results in a drastically increased rate of aggregation. In comparison, Leukocare's HighCon antibody formulation (blue) achieved a 2-fold higher concentration while stably preventing any increase in aggregate formation over time.
Why high concentration matters
Why high concentration matters
